The Inhibition of Pancreatic Cancer Progression by K-Ras-overexpressing Mesenchymal Stem Cell-derived Secretomes

Overview

Journal Sci Rep

Specialty Science

Date 2023 Sep 12

PMID 37699930

Authors

Qingji Huo

Kexin Li

Xun Sun

Adam Zhuang

Kazumasa Minami

Keisuke Tamari

Kazuhiko Ogawa

Melissa L Fishel

Bai-Yan Li

Hiroki Yokota

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor survival. To explore an uncharted function of K-Ras proto-oncogene, K-Ras was activated in mesenchymal stem cells (MSCs) and the effects of MSC conditioned medium (CM) on PDAC were examined. Overexpression of K-Ras elevated PI3K signaling in MSCs, and K-Ras/PI3K-activated MSC-derived CM reduced the proliferation and migration of tumor cells, as well as the growth of ex vivo freshly isolated human PDAC cultures. CM's anti-tumor capability was additive with Gemcitabine, a commonly used chemotherapeutic drug in the treatment of PDAC. The systemic administration of CM in a mouse model suppressed the colonization of PDAC in the lung. MSC CM was enriched with Moesin (MSN), which acted as an extracellular tumor-suppressing protein by interacting with CD44. Tumor-suppressive CM was also generated by PKA-activated peripheral blood mononuclear cells. Collectively, this study demonstrated that MSC CM can be engineered to act as a tumor-suppressive agent by activating K-Ras and PI3K, and the MSN-CD44 regulatory axis is in part responsible for this potential unconventional option in the treatment of PDAC.

References

Adhikari H, Kattan W, Kumar S, Zhou P, Hancock J, Counter C . Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Nat Commun. 2021; 12(1):5248. PMC: 8429657. DOI: 10.1038/s41467-021-25523-5. View

Xu W, Wan Q, Na S, Yokota H, Yan J, Hamamura K . Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13. Cell Signal. 2015; 27(12):2332-42. DOI: 10.1016/j.cellsig.2015.08.014. View

Sun X, Li K, Aryal U, Li B, Yokota H . PI3K-activated MSC proteomes inhibit mammary tumors via Hsp90ab1 and Myh9. Mol Ther Oncolytics. 2022; 26:360-371. PMC: 9420348. DOI: 10.1016/j.omto.2022.08.003. View

Li K, Sun X, Li B, Yokota H . Conversion of Osteoclasts into Bone-Protective, Tumor-Suppressing Cells. Cancers (Basel). 2021; 13(22). PMC: 8615769. DOI: 10.3390/cancers13225593. View

Liu S, Sun X, Li K, Zha R, Feng Y, Sano T . Generation of the tumor-suppressive secretome from tumor cells. Theranostics. 2021; 11(17):8517-8534. PMC: 8344019. DOI: 10.7150/thno.61006. View

Sun X, Li K, Figueiredo M, Lin C, Li B, Yokota H . Generation of the Chondroprotective Proteomes by Activating PI3K and TNFα Signaling. Cancers (Basel). 2022; 14(13). PMC: 9264838. DOI: 10.3390/cancers14133039. View

Sun X, Li K, Hase M, Zha R, Feng Y, Li B . Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling. Theranostics. 2022; 12(2):929-943. PMC: 8692912. DOI: 10.7150/thno.66148. View

Liu Q, Zhang R, Michalski C, Liu B, Liao Q, Kleeff J . Surgery for synchronous and metachronous single-organ metastasis of pancreatic cancer: a SEER database analysis and systematic literature review. Sci Rep. 2020; 10(1):4444. PMC: 7064579. DOI: 10.1038/s41598-020-61487-0. View

Thein K, Biter A, Hong D . Therapeutics Targeting Mutant KRAS. Annu Rev Med. 2020; 72:349-364. DOI: 10.1146/annurev-med-080819-033145. View

10.

Fulop D, Zylberberg H, Wu Y, Aronson A, Labiner A, Wisnivesky J . Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy. JAMA Netw Open. 2023; 6(3):e234254. PMC: 10037151. DOI: 10.1001/jamanetworkopen.2023.4254. View

11.

Keleg S, Buchler P, Ludwig R, Buchler M, Friess H . Invasion and metastasis in pancreatic cancer. Mol Cancer. 2003; 2:14. PMC: 149416. DOI: 10.1186/1476-4598-2-14. View

12.

Li K, Sun X, Zha R, Liu S, Feng Y, Sano T . Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs. Theranostics. 2022; 12(7):3084-3103. PMC: 9065181. DOI: 10.7150/thno.70549. View

13.

Senoo-Matsuda N, Johnston L . Soluble factors mediate competitive and cooperative interactions between cells expressing different levels of Drosophila Myc. Proc Natl Acad Sci U S A. 2007; 104(47):18543-8. PMC: 2141813. DOI: 10.1073/pnas.0709021104. View

14.

Heller D, Nicolson N, Ahuja N, Khan S, Kunstman J . Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surg. 2019; 155(2):e195047. PMC: 6902102. DOI: 10.1001/jamasurg.2019.5047. View

15.

Baleeiro R, Bouwens C, Liu P, Di Gioia C, Chard Dunmall L, Nagano A . MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Oncoimmunology. 2022; 11(1):2080329. PMC: 9154752. DOI: 10.1080/2162402X.2022.2080329. View

16.

Jones S, Zhang X, Parsons D, Cheng-Ho Lin J, Leary R, Angenendt P . Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-6. PMC: 2848990. DOI: 10.1126/science.1164368. View

17.

Li K, Sun X, Minami K, Tamari K, Ogawa K, Li H . Proteomes from AMPK-inhibited peripheral blood mononuclear cells suppress the progression of breast cancer and bone metastasis. Theranostics. 2023; 13(4):1247-1263. PMC: 10008730. DOI: 10.7150/thno.80294. View

18.

Sano T, Sun X, Feng Y, Liu S, Hase M, Fan Y . Inhibition of the Growth of Breast Cancer-Associated Brain Tumors by the Osteocyte-Derived Conditioned Medium. Cancers (Basel). 2021; 13(5). PMC: 7959137. DOI: 10.3390/cancers13051061. View

19.

Torphy R, Fujiwara Y, Schulick R . Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020; 50(10):1117-1125. PMC: 7837389. DOI: 10.1007/s00595-020-02028-0. View

20.

Skoulidis F, Li B, Dy G, Price T, Falchook G, Wolf J . Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25):2371-2381. PMC: 9116274. DOI: 10.1056/NEJMoa2103695. View